Article

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Leukemia
DOI: 10.1038/leu.2015.274
54Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.
Get full text

Cite

CITATION STYLE

APA

Cavo, M., Pantani, L., Pezzi, A., Petrucci, M. T., Patriarca, F., Di Raimondo, F., … Sonneveld, P. (2015, December 1). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia. Nature Publishing Group. https://doi.org/10.1038/leu.2015.274

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free